StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective on the stock.

Lipocine Trading Down 0.4 %

Shares of NASDAQ LPCN opened at $4.86 on Wednesday. The stock has a market cap of $25.99 million, a price-to-earnings ratio of -6.39 and a beta of 1.24. The stock’s 50-day moving average is $5.06 and its 200 day moving average is $5.28. Lipocine has a 1-year low of $2.82 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, analysts forecast that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.